Synthesis, Characterization, Antimicrobial Properties, and Antioxidant Activities of Silver-N-Heterocyclic Carbene Complexes

Table 2

Minimal inhibitory concentration micro mol/L of salts 2 and silver-NHCs complexes 3 against bacterial and fungal strains.

Compounds	Bacteria^[a]					Fungi^[b]
	Gram-negative			Gram-positive
	EC	PA	KP	SA	MRSA	CA
2a	21 ± 0.3	42 ± 1.2	22 ± 0.3	11 ± 0.2	13 ± 0.3	8 ± 0.1
2b	24 ± 0.4	52 ± 1.3	20 ± 0.7	12 ± 0.5	12 ± 0.4	12 ± 0.3
2c	22 ± 0.2	32 ± 0.7	10 ± 0.1	10 ± 0.1	11 ± 0.3	11 ± 0.2
2d	39 ± 0.3	36 ± 0.3	25 ± 1.2	12 ± 0.5	13 ± 0.4	12 ± 0.3
2e	23 ± 0.6	22 ± 0.2	23 ± 0.7	13 ± 0.4	25 ± 1.2	11 ± 0.2
2f	18 ± 0.5	28 ± 0.4	12 ± 0.3	12 ± 0.2	12 ± 0.1	13 ± 0.2
2g	29 ± 0.7	37 ± 0.2	22 ± 1.2	11 ± 0.3	21 ± 0.8	23 ± 1.2
2h	23 ± 0.2	24 ± 1.1	23 ± 0.7	12 ± 0.3	20 ± 0.8	11 ± 0.4
2i	22 ± 0.3	24 ± 1.2	24 ± 0.8	12 ± 0.4	24 ± 0.8	10 ± 0.2
2j	18 ± 0.4	33 ± 0.8	25 ± 0.4	11 ± 0.1	13 ± 0.5	9 ± 0.4
3a	26 ± 0.7	80 ± 1.8	22 ± 0.6	15 ± 0.3	11 ± 0.2	8 ± 0.6
3b	51 ± 0.6	100 ± 1.7	28 ± 1.3	12 ± 0.5	12 ± 0.4	16 ± 0.3
3c	26 ± 0.3	51 ± 1.2	14 ± 0.2	14 ± 0.6	13 ± 0.4	14 ± 0.3
3d	52 ± 0.8	98 ± 1.8	29 ± 1.3	16 ± 0.5	11 ± 0.4	13 ± 0.3
3e	23 ± 0.8	26 ± 1.3	24 ± 0.8	12 ± 0.4	27 ± 1.1	15 ± 0.2
3f	26 ± 0.7	52 ± 1.7	19 ± 0.4	11 ± 0.3	13 ± 0.2	14 ± 0.3
3g	51 ± 1.3	51 ± 1.6	22 ± 0.7	14 ± 0.5	28 ± 0.6	27 ± 0.4
3h	26 ± 0.8	27 ± 0.8	26 ± 0.9	12 ± 0.4	26 ± 0.7	14 ± 0.2
3i	27 ± 0.9	24 ± 0.9	24 ± 0.8	17 ± 0.2	27 ± 0.5	13 ± 0.2
3j	25 ± 0.7	49 ± 1.5	26 ± 0.9	18 ± 0.6	17 ± 0.2	8 ± 0.1
Ampicillin	18 ± 0.5	—	3 ± 0.2	10 ± 0.2	—	—
Fluconazole	—	—	—	—	—	3.12 ± 0.2

^[a]EC: Escherichia coli (ATCC 25988). PA: Pseudomonas aeruginosa (ATCC 27853). KP: Klebsilla pneumonia (ATCC 700603). SA: Staphylococcus aureus (ATCC 29213). MRSA: Methicillin-resistant Staphylococcus aureus (ATCC 43300). ^[b]CA: Candida albicans (ATCC 14053). Bold values represent the number of the synthesized compounds.